Alnylam Pharmaceuticals (ALNY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.84
- Estimate
- $2.14
- Surprise
- -14.2%
- Revenue (period 2026-06-30)
- $1.29B
- Score at report (before → after)
- 6.5 → 6.8/10
Revenue source: mixed.
How the report landed
Alnylam Pharmaceuticals (ALNY) missed the $2.14 estimate with diluted EPS of $1.84 — a large 14.2% shortfall. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALNY Buy (Wait) at 6.9/10.
2 of the last 4 quarters beat the estimate; this quarter's -14.2% surprise compares with a +17.7% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- High-quality business
- Strong growth profile
What argues against it
- Leverage penalty (D/E 2.2): -1.5
- Consecutive earnings misses (2)
- Below 200-MA, MA slope -8.9%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $236.70
- Entry target
- $219.22
- Price target
- $333.18
- Stop
- $199.52
- Upside to target
- +40.8%
- Reward-to-risk
- 2.7:1
The stock trades at 41.2× trailing but 18.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-08-24 — shown for context, not personalized investment advice.
ALNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $31.61B
- P/E (fwd)
- 18.8
- P/E (ttm)
- 41.2
- 52-week range
- $197.81–$495.55
- Off 52-week high
- 52.2%
- RSI (14)
- 60
- Volume vs avg
- 0.80×
- Score today
- 6.9/10